This document provides an overview of precision medicine and pharmacogenomics. It discusses barriers to implementing pharmacogenomic testing, key medical settings and patient populations to target, and considerations for integrating test results into clinical workflows. Evidence is presented showing pharmacogenomic testing can reduce adverse drug reactions and alter prescribing. The document emphasizes engaging patients and generating more evidence of the clinical value and economic benefits of pharmacogenomic testing.